About Us
We are an AI-driven company dedicated to transforming the biologics manufacturing industry, such as the production of antibodies, proteins, mRNA, cell & gene therapies, etc via T cells, CHO cells, NK cells, IPSCs and beyond. Our mission is to improve patients' access to the most innovative biologics, starting with the pressing challenges in R&D and manufacturing.
Our Technology
ChemT’s proprietary AI-driven cellular drug discovery (AICD) platform is the core of our innovation. Leveraging cutting-edge artificial intelligence, we design and deliver small molecules to make biologics production more robust and scalable. By optimizing the yield and efficacy of biological treatments, our platform offers a new approach to improving the performance and accessibility of life-changing therapies.
Our Breakthrough
Our flagship asset, Chemplify™ , is now commercially available for the T cell therapeutic manufacturing. As a formulated anti-senescent solution containing patented small molecules, Chemplify™ achieves 5-10x higher T cell yield with significantly enhanced quality. Its proven in vitro and in vivo efficacy sets a new industry benchmark, enabling more effective and scalable immunotherapies for cancer. Our pipelines include more ground-breaking and innovative small molecules with novel targets, novel structures, and novel mechanisms of action for various cell activities.
Our Vision
Our vision goes beyond a single compound. We strive to replace traditional components like human serum and cytokines with small-molecule solutions that establish a chemically defined, consistent, and high-quality culture environment. Beyond T cells, our research and development pipeline focuses on optimizing CHO cells and advancing antibody generation, further amplifying the reach of our AI-driven biotech innovations. Other areas we work on include B cells, NK cells, stem cells, IPSC, etc.
SCALABLE AND CUTTING-EDGE AI PLATFORM
Our advanced AI platform enables rapid identification of targets, and de novo development and optimisation of small molecules with targeted biological effects. Using this platform, we create models to discover targets whose modulation enhances cell activities, and the ideal structure of the molecule that unlocks the cells’ potential in the biologics manufacturing.
Our AI platform has active pipelines in various cell types across different modalities, including small molecules, antibodies, mRNA, etc. We partner with world-leading institutions on the R&D, and serve biotechs, pharma, CDMOs and hospitals with world-class assets.
Product List
Our flagship product, Chemplify, is a small molecule that enhances T cell therapy by boosting T cell expansion 5-10 times and promoting a younger, healthier state via a novel pathway. This innovation addresses key challenges in T-cell therapeutic manufacturing and presents a unique opportunity to explore an uncharted mechanism that could reshape our understanding of T cell biology.
Future Pipelines
-
Our AI-designed cellular drugs enhance CHO cell productivity by precisely modulating cellular pathways to increase recombinant protein yield and stability.
-
Our AI creates cellular drugs that help hoscells produce more AAVs, making gene therapy manufacturing quicker and more efficient.
-
Customize the solution to your manufacturing bottleneck with our proprietary AI platform and wet labs!
